Compare HFWA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | ORIC |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | 755 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1997 | 2020 |
| Metric | HFWA | ORIC |
|---|---|---|
| Price | $28.47 | $8.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $32.60 | $21.71 |
| AVG Volume (30 Days) | 286.0K | ★ 2.1M |
| Earning Date | 10-22-2026 | 11-16-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 58.06 | 19.67 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.72 | N/A |
| Revenue Next Year | $7.95 | N/A |
| P/E Ratio | $32.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.32 | $7.23 |
| 52 Week High | $31.25 | $14.68 |
| Indicator | HFWA | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 35.23 |
| Support Level | $26.49 | $7.62 |
| Resistance Level | $28.45 | $9.13 |
| Average True Range (ATR) | 0.70 | 1.09 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 39.64 | 9.36 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.